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Aberrant cell-surface sialylation patterns have been shown to correlate with 1 
tumor progression and metastasis. However, the role of sialylation regulation of 2 
cancer multidrug resistance (MDR) remains poorly understood. The present 3 
study investigated sialylation in modification on MDR in acute myeloid leukemia 4 
(AML). Using mass spectrometry (MS) analysis, the composition profiling of 5 
sialylated N-glycans differed in three pairs of AML cell lines. Real-time 6 
polymerase chain reaction (PCR) showed the differential expressional profiles of 7 
20 sialyltransferase (ST) genes in the both AML cell lines and bone marrow 8 
mononuclear cells (BMMC) of AML patients. The expression levels of ST3GAL5 9 
and ST8SIA4 were detected, which were over-expressed in HL60 and HL60/ADR 10 
cells. The altered levels of ST3GAL5 and ST8SIA4 were found in close 11 
association with the MDR phenotype changing of HL60 and HL60/ADR cells 12 
both in vitro and in vivo. Further data demonstrated that manipulation of these 13 
two genes’ expression modulated the activity of phosphoinositide-3 kinase 14 
(PI3K)/Akt signaling pathway and its downstream target thus regulated the 15 
proportionally mutative expression of P-glycoprotein (P-gp) and multidrug 16 
resistance related protein 1 (MRP1), both of which are known to be involved in 17 
MDR. Blocking the PI3K/Akt pathway by its specific inhibitor LY294002 or by 18 
Akt small interfering RNA (siRNA) resulted in the reduced chemosensitivity of 19 
HL60/ADR cells. Therefore this study indicated that sialylation involved in the 20 
development of MDR of AML cells probably through ST3GAL5 or ST8SIA4 21 


























Acute myeloid leukemia (AML), the most common type of leukemia in adults, has the 2 
lowest survival rate among all leukemias.1 It is a clonal malignancy of the 3 
hematopoietic system characterized by accumulation of immature cell populations in 4 
the bone marrow or peripheral blood.2 Multidrug resistance (MDR) is a major 5 
challenge to the successful treatment of AML. Classic MDR is the consequence of 6 
overexpression of transporter proteins e.g., P-gp and MRP1 belonging to the ATP 7 
binding cassette (ABC) family which lead to lower intracellular drug accumulation 8 
and thus reduce cellular toxicity of chemotherapeutic agents.3 Nowadays, many 9 
researchers are struggling to adequately evaluate the relationship between glycan 10 
alterations and resistance to chemotherapy of cancer cells. However, there is still little 11 
information about the role of glycosyltransferases in the development of leukemia 12 
MDR in spite of the modification of glycan structures have been observed in 13 
drug-resistance leukemia cells.4, 5 14 
Cell-surface glycoproteins commonly contain sialic acid (SA) as a 15 
monosaccharide located on the nonreducing terminus of glycans. Evidence from both 16 
patient histochemical analysis and experimental tumor models demonstrates that 17 
altered sialylation involves in a variety of biological processes, including cell-cell 18 
communication, cell-matrix interaction, adhesion, and protein targeting.6,7   19 
Sialyltransferases (ST) is a family of anabolic enzymes, consisting of 20 members that 20 
are subjected into three subfamilies. These glycosyltransferases convert sialic acid 21 
from cystidine-5-monophospho-N-acetylneuraminic acid (CMP-NeuAc) to 22 
 5
glycoproteins or glycolipids.8 Alpha-2, 3-sialyltransferases mediate the transfer of 1 
sialic acid with an alpha 2, 3-linkage to it with terminal Gal residues (ST3Gal I-VI). 2 
Alpha-2, 6-sialyltransferases mediate the transfer of sialic acid with an alpha 2, 3 
6-linkage to it with terminal Gal (ST6Gal I-II) or GalNAc residues (ST6GalNAc I-VI). 4 
Alpha-2, 8-sialyltransferases mediate the transfer of sialic acid with an alpha 2, 5 
8-linkage (ST8Sia I-VI) to it with other SA residues.9 6 
Although the modification of sialylation in solid tumors has been documented in 7 
details, 10, 11 there are not many reports in case of blood cancer. ST3Gal V was found 8 
predominantly expressed in childhood acute lymphoblastic leukemia (ALL).12 High 9 
level of ST3Gal III, an enzyme catalyzing Sialyl-Lewis X (SLX) synthesis, produced 10 
cellular resistance to Taxol and thus reduced the efficacy of Taxol therapy.13 Elevated 11 
mRNA levels of ST6Gal I and ST3Gal V positively correlated with the high risk of 12 
pediatric acute leukemia.12 Endogenous expression of ST6GalNAc I in CML cell line 13 
K562 was associated with the expression of the STn O-Glycan related to a lack of 14 
response to chemotherapy.14 Yamada et al confirmed ST6GalNAc IV as the major 15 
enzyme controlling the expression of sialyl-T antigen in leukemia cell lines.15 ST8Sia 16 
I (GD3 synthase) was down regulated in childhood ALL while was up-regulated in 17 
adult T-cell leukemia cell lines.12 Polysialic acid (PSA) formed by ST8Sia II and 18 
ST8Sia IV has been found on the unidentified proteins in basophilic leukemia cell 19 
lines.16 In order to inhibit MDR of AML targeting of ST genes could be applied to 20 
cancer therapy. 21 
Phosphoinositide 3 kinase (PI3K) /Akt signaling activation is implicated involving 22 
 6
in the progression of a wide variety of neoplasias.17 Recent studies illustrate that 1 
aberrant activation of PI3K/Akt pathway leads to the short-term survival and drug 2 
resistance of different types of human neoplasm cells.18, 19 Activation of Akt is 3 
associated with poor prognosis and chemotherapeutic resistance in pediatric 4 
B-precursor acute lymphoblastic leukemia.20 However, little is known regarding the 5 
PI3K/Akt signaling pathways on ST-mediated leukemia MDR. 6 
In order to understand the role of ST gene family in regulation of MDR in AML, 7 
the present study aimed to investigate the sialylated oligosaccharide alterations and 8 
mRNA expression levels of ST genes in three pairs of AML cell lines and in BMMC 9 
isolated from the diagnostic AML patients, as well as the possible mechanisms via 10 
PI3K/Akt pathway. 11 
 12 
RESULTS 13 
MALDI-MS analysis of N-glycan composition profiling from AML cell lines 14 
MALDI-TOF MS analysis was utilized to evaluate the N-glycan composition 15 
profiling of HL60 and HL60/ADR cell lines. Fig. 1 showed the MS spectra of 16 
N-glycans released from cell membranes and the observed MS signals of the 17 
N-glycans (peaks 1-35 in Figure 1a) and the assigned N-glycan signals were 18 
summarized in Table 4. The observed signal intensities in the mass spectra were 19 
presented as a histogram (Figure 1b), with the estimated monosaccharide composition. 20 
High-mannose glycans (peak 4, 6, 9, 13 and 16) were observed in both cell lines 21 
(Table 4). The N-glycans detected in HL60/ADR cells showed remarkably different 22 
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profiles vs those of HL60 cells. The peaks at 5 and 30 were exclusively detected only 1 
in the HL60/ADR cell line. HL60/ADR cells also showed higher incidence of 2 
additional significant peaks at 1, 2, 7, 10, 11, 17, 21, 23, 31 and 34 (≥2 fold). Peak 14, 3 
15, 25 and 28 (≥2 fold) clearly showed a significant increase in HL60 cell line. 4 
Surprisingly, the most significant increase peaks corresponding to sialylated 5 
oligosaccharides were observed at peak 17, 21, 23, 31 and 34 in HL60/ADR cells. 6 
The sialylated oligosaccharides observed at peaks 15, 25 and 28 also showed 7 
significant increase in HL60 sample.  8 
 9 
Differential expression of ST family in three pairs of AML cell lines  10 
Real-time PCR analysis showed that the expression of ST gene family was differed 11 
between the three pairs of AML cell lines. A common feature was that the expression 12 
levels of ST8SIA4 (5.81 folds), ST6GAL1 (4.56 folds), ST3GAL4 (3.18 folds) and 13 
ST6GALNAC4 (3.01 folds) were remarkably high in three MDR cells. In addition, 14 
drug sensitive cells showed higher expressional levels of ST3GAL5 (5.19 folds), 15 
ST8SIA6 (4.17 folds) and ST3GAL1 (2.72 folds). No statistically significant 16 
differences were found in the expression levels of ST3GAL2, ST3GAL3, ST6GAL2, 17 
ST6GALNAC1, ST6GALNAC2, ST6GALNAC6, ST8SIA1 and ST8SIA5 mRNA, 18 
while ST3GAL6, ST6GALNAC3, ST6GALNAC5, ST8SIA2 and ST8SIA3, were 19 
undetectable in both drug-sensitive cells and MDR cells ( Figure 2a-e). 20 
 21 
Altered expression of ST8SIA4 modulates chemosensitivity of AML cells in vitro and 22 
 8
in vivo 1 
Due to the significant increase of ST8SIA4 mRNA expression in HL60/ADR cells, 2 
ST8SIA4 was silenced, by shRNA, so as to elucidate its direct effect on the 3 
chemosensitivity of HL60/ADR cells. As shown in Figure 3a.b, the expression level 4 
of ST8SIA4 was significantly reduced in HL60/ADR-shRNA transfectants compared 5 
with those in the controls both at transcription and protein level. Furthermore, α-2, 8 6 
sialylation level detected by FITC-conjugated Siglec7 on the cell surface, was also 7 
found reduced in HL60/ADR-ST8SIA4 shRNA1 cells (Figure 3c).  8 
As depicted in Figure 3d, in addition to adriamycin, HL60/ADR cells were also 9 
resistant to other chemotherapeutic drugs including paclitaxel and vincristine. The 10 
IC50 values for the drugs were greater in the HL60/ADR group than those in the HL60 11 
group (Figure 3d), which indicated that HL60/ADR cells awarded MDR 12 
characteristics.  The IC50 values for the drugs were significantly less in the 13 
HL60/ADR-ST8SIA4 shRNA1 groups than those in the HL60/ADR-control shRNA 14 
groups, suggesting that cell proliferation was inhibited and chemosensitivity was 15 
remarkably restored (Figure 3d).   16 
Nude mice bearing HL60, HL60/ADR, HL60-control shRNA and 17 
HL60/ADR-ST8SIA4 shRNA1 xenografts were used to determine the treatment 18 
efficacy of adriamycin by measuring tumor volumes. Figure 3e showed that a 19 
significant reduction of mean tumor volume of HL60 tumors was observed, as 20 
compared with HL60/ADR groups. The mean tumor volume was significantly less in 21 
the HL60/ADR-ST8SIA4 shRNA1 groups than those in the HL60/ADR-control 22 
 9
shRNA groups, and the effect of concomitant application of adriamycin. IHC staining 1 
analysis of the tumor sections revealed that the expression of ST8sia IV was 2 
decreased in the mouse group treated with ST8SIA4 shRNA1 compared to that in 3 
untreated group (Fig. 3f).  4 
To further investigate the effect of ST8SIA4 on chemoresistance, ST8SIA4 5 
expression vector was transfected in HL60 cells and higher expression levels of 6 
ST8SIA4 were detected in HL60/ST8SIA4 cells (Figure 4a.b.c.f). The 7 
chemoresistance of HL60 cells was increased after the transfection of the ST8SIA4 8 
expression vector in vitro and in vivo (Figure 4d.e).  9 
   We evaluated the expression of relevant substrate in the aberrantly expressed 10 
ST8SIA4 cell lines. CD147 is N-glycoprotein, which was analyzed by way of 11 
immunoprecipitation (IP). A remarkable change of CD147 expression was observed 12 
in HL60/ADR-ST8SIA4 shRNA1 and HL60/ST8SIA4 cells compared to those in the 13 
control cells. Siglec7 lectin blotting also showed the same tendency, suggesting that 14 
CD147 was a specific substrate of ST8SIA4 sialyltransferase (Supplementary Figure 15 
S1a, b). 16 
 17 
Altered expression of ST3GAL5 regulates chemosensitivity of AML cells in vitro and 18 
in vivo  19 
As it was found that the mRNA and protein levels of ST3GAL5 were decreased 20 
notably in HL60-ST3GAL5 shRNA transfectants (Figure 5a.b), we targeted 21 
ST3GAL5 to determine whether changed expression of ST3GAL5 could influence 22 
 10
chemosensitivity of HL60 and HL60/ADR cells. Fluorescence intensity on MAL 1 
revealed less α-2, 3 sialylation in HL60-ST3GAL5 shRNA1 cells than that in control 2 
cells, since lower fluorescence intensity of lectin was corresponding with lower 3 
expression of glycogene (Figure 5c)  4 
MTT assay results showed that the IC50 values for the drugs were greater in the 5 
HL60/ADR group than those in the HL60 group (Figure 5d). The IC50 values for the 6 
drugs were significantly increased in HL60-ST3GAL5 shRNA1 cells groups 7 
compared to those in the HL60-control shRNA groups (Figure 5d).  8 
Tumor volumes were measured and compared between the groups with or 9 
without adriamycin treatment. Figure 5e displayed that a significant reduction of 10 
mean tumor volume of HL60 tumors was observed, as compared with HL60/ADR 11 
groups. In the group of mice bearing HL60 tumors, tumor volumes with adriamycin 12 
treatment were lower than those without. But in the group of mice bearing 13 
HL60-ST3GAL5 shRNA tumors, tumor volumes increased significantly even after 14 
adriamycin treatment. Reduced expression level of ST3Gal V in tumor cells of 15 
HL60-ST3GAL5 shRNA1 was also validated by IHC staining (Figure 5f). 16 
In order to determine whether over-expression of ST3GAL5 could enhance 17 
chemosensitivity of HL60/ADR cells, HL60/ADR cells were then transfected with 18 
ST3GAL5 expression vector and higher levels of ST3GAL5 were detected in 19 
HL60/ADR/ST3GAL5 cells (Figure 6a.b). The chemosensitivity of HL60/ADR cells 20 
was increased with the ST3GAL5 expression vector transfection in vitro and in vivo 21 
(Figure 6d.e). IHC staining and flow cytometry analysis revealed elevated expression 22 
 11
of ST3Gal V in HL60/ADR/ST3GAL5 cells (Figure 6c.f). 1 
Futher on, we investigated the expression of relevant substrate in the aberrantly 2 
expressed ST3GAL5 cell lines. CD147 and MAL lectin showed no difference in 3 
expression among the six groups, suggesting that CD147 was not a relevant substrate 4 
of ST3GAL5 sialyltransferase (Supplementary Figure S1c, d). 5 
 6 
Effect of ST3GAL5 or ST8SIA4-activated PI3K/Akt signaling pathway on the 7 
expression of P-gp and MRP1 8 
Here, we investigated whether ST3GAL5 or ST8SIA4 activated the PI3K/Akt 9 
pathway and whether this pathway was involved in ST3GAL5 or ST8SIA4-mediated 10 
cell MDR. Western blotting (Figure 7b.c) showed that the levels of the main 11 
molecules of PI3K/Akt signaling pathway, P110α (the catalytic subunit of PI3K), 12 
phosphorylation Akt at Ser473 and Thr308, and its downstream effector NF-κB were 13 
significantly increased in HL60/ST8SIA4 cells and HL60-ST3GAL5 shRNA1 cells, 14 
while decreased in HL60/ADR/ST3GAL5 cells and HL60/ADR-ST8SIA4 shRNA1 15 
cells (Figure 7a.d). However, there was no change in the total amount of Akt protein. 16 
Interestingly, we also revealed the same tendency of PI3K/Akt/mTOR pathway on 17 
stimulation with ST3GAL5 or ST8SIA4 (Supplementary Figure S2). 18 
Moreover, we investigated whether ST3GAL5 or ST8SIA4 could influence the 19 
expression of P-gp and MRP1. Interestingly, flow-cytometric analysis (Figure 7f.g) 20 
illustrated that elevated expression levels of P-gp and MRP1 were detected in 21 
HL60/ST8SIA4 cells and HL60-ST3GAL5 shRNA1 cells compared to those in the 22 
 12
control groups. In addition, HL60/ADR cells expressed lower levels of P-gp and 1 
MRP1 with ST8SIA4 suppression and ST3GAL5 overexpression. (Figure 7e.h)  2 
 3 
PI3K/Akt inhibition modulates the chemoresistance of HL60/ADR cells both in vitro 4 
and in vivo 5 
The effect of PI3K/Akt signaling activity on chemoresistance of HL60/ADR cells was 6 
explored by pharmacologic inhibition of the PI3K/Akt pathway. By western blotting, 7 
HL60/ADR cells treated with LY294002 or Akt siRNA exhibited apparently 8 
decreased expression levels of the main signal molecules of PI3K/Akt pathway 9 
(Figure 8a). As seen in Figure 8b, the inhibition of PI3K/Akt pathway resulted in the 10 
HL60/ADR cells susceptible to chemotherapy. The similar results were also obtained 11 
in in vivo chemosensitivity analysis that reduced tumor volumes were detected in 12 
mouse group bearing HL60/ADR tumors with impaired PI3K/Akt signaling (Figure 13 
8c). Altered expression levels of the main signal molecules of PI3K/Akt pathway in 14 
mouse group bearing HL60/ADR tumors with LY294002 or Akt siRNA treatment 15 
were also validated by IHC staining, as shown in Figure 8d. Moreover, the inhibitor of 16 
PI3K/Akt or silencing Akt reduced the expression of P-gp and MRP1 (Figure 8e).  17 
 18 
Differential expression of ST gene family in AML patients 19 
Expression of MDR-related marker, ST gene family presenting in BMMC of AML 20 
patients is summarized in Table 4. The frequency of P-gp positivity was 90.8% (69 of 21 
76) in the AML patients. The BMMC were first divided into six groups, M2, 22 
 13
M2/MDR, M3, M3/MDR, M5 and M5/MDR, and were evaluated the mRNA 1 
expression level of ST gene family. The groups of M2/MDR, M3/MDR and M5/MDR 2 
showed significantly high ST3GAL4 (P=0.002; P=0.006; P=0.009), ST6GAL1 3 
(P=0.004; P=0.002; P=0.004), ST6GALNAC4 (P=0.003; P=0.001; P=0.003) and 4 
ST8SIA4 (P=0.001; P=0.004; P=0.008) mRNA expression compared to those of the 5 
chemosensitive group. In contrast, group of M2, M3, M5 without MDR showed 6 
significantly up regulated ST3GAL1 (P=0.032; P=0.002; P=0.025), ST3GAL5 7 
(P=0.001; P=0.001; P=0.003) and ST8SIA6 (P=0.002; P=0.001; P=0.002) expression 8 
compared to AML/ADR group. Expression of the other members of ST family 9 
showed no difference between the two groups, while ST3GAL6, ST6GALNAC3, 10 
ST6GALNAC5, ST8SIA2 and ST8SIA3 were detected slightly.  11 
 12 
DISCUSSION 13 
MDR is the major obstacle to the efficiency of chemotherapy in the treatment of 14 
leukemia.21 In this study, we explored the possible mechanism of sialylation 15 
modification on MDR in hunman AML cell lines. We also investigated the 16 
differential expression of ST family, which was reported to be correlated with 17 
clinicopathological characteristics in AML patients. 18 
  Recent development in mass spectrometry (MS) technology has fueled high 19 
throughput analyses of glycoproteins.22, 23 MS technology as a novel methodology 20 
provides high sensitivity and more rapid glycan analysis.24 Zhang et al have 21 
investigated novel N-glycan changes involved in MDR between leukemia cell line 22 
 14
K562 and adriamycin resistant K562/ADR by MALDI-TOF/MS.5 To identify 1 
sialylated N-glycan associated with MDR of human AML, we used MS method to 2 
analyze the composition profiling of N-glycans. We compared the total N-glycans 3 
from HL60 and HL60/ADR cell lines, and found dramatic differences in N-glycan 4 
profiles between these two groups (Figure 1, Table 4). A major population of 5 
N-glycans detected in HL60 and HL60/ADR cells was corresponded to high-mannose 6 
structures (peak 4, 6, 9, 13 and 16). The peaks at 5 and 30 were exclusively detected 7 
only in the HL60/ADR cell line. Major peaks (peak 1, 2, 7, 10, 11, 17, 21, 23, 31 and 8 
34) corresponded to sialylated oligosaccharides originating from HL60/ADR cells 9 
showed a significant increase (≥2 fold). Moreover, peaks 14, 15, 25 and 28 10 
corresponded to sialylated oligosaccharides originating from HL60 cells also showed 11 
a significant increase (≥2 fold). Therefore, monitoring of the sialylated N-glycan 12 
profile would be an important step in the prevention of tumor MDR and would 13 
increase our understanding of MDR mechanisms.  14 
Aberrant expression of sialylated glycans in various cancers is recognized as 15 
prognostic factors and potential targets for therapeutic approaches.25 Malignant cell 16 
surface properties are generally changed, which mainly due to altered 17 
sialoglycoconjugates expressed on the plasma membrane.26 The biosynthetic pathway 18 
of sialylated glycans in leukemia pathogenesis highlighted the importance of ST in 19 
AML. In this study, we revealed the differential expression of ST genes in three pairs 20 
of AML cell lines. All MDR cells were characterized by higher levels of ST8SIA4 21 
(5.81fold, Figure 2) while parental cells expressed more ST3GAL5 (5.19 fold), 22 
 15
suggesting that the AML cell lines displayed altered α2, 3- and α2, 8-linked 1 
sialylation.  2 
ST3GAL5 encodes Lactosylceramide α-2, 3-sialyltransferase that catalyzes the 3 
formation of ganglioside GM3. GM3 is a sialylated trisaccharide antigen richly 4 
expressed by a number of tumors and thus becomes an important molecular target in 5 
the development of novel diagnostic and therapeutic strategies for cancers.27 ST8SIA4 6 
encodes N-acetylgalactosaminide α-2, 8-sialyltransferase IV (ST8Sia IV) that 7 
catalyzes the polycondensation of α-2, 8-linked sialic acid required for the synthesis 8 
of polysialic acid, a modulator of the adhesive properties of neural cell adhesion 9 
molecule (NCAM) which is implicated in tumor formation/metastasis.28 It is of 10 
interest to know whether the change of ST3GAL5 or ST8SIA4 confers the alteration 11 
of MDR is in leukemia cells. Our former work demonstrated that the expression of 12 
ST3GAL5 or ST8SIA4 involved in drug resistance development in chronic myeloid 13 
leukemia (CML) cell lines K562 and K562/ADR.5 The present investigation 14 
illustrated that the altered level of ST3GAL5 or ST8SIA4 led to drug-resistant 15 
phenotype changes of HL60 and HL60/ADR cells both in vitro and in vivo (Figure 3, 16 
4, 5, 6). Based on these results we hypothesized that ST3GAL5 or ST8SIA4 might 17 
function as a pivotal modulator to MDR in AML. 18 
N-glycans bind proteins, and the combinations of glycan and protein may be 19 
important for their function. 29, 30 In this study, we analyzed the expressions of CD147 20 
in AML cell lines to identify specific, relevant substrates of the aberrantly expressed 21 
sialyltransferases. CD147 is a highly N-glycosylated immunoglobulin superfamily 22 
 16
transmembrane protein that is composed of two extracellular Ig domains, which 1 
contribute to a highly N-glycosylated HG-CD147 (~40–60 kDa) and a low 2 
glycosylated form, LG-CD147 (~33 kDa). 31 Our previous results showed that altered 3 
N-glycosylation of CD147 was found in K562/ADR cells, and further suggested a link 4 
between defective N-glycosylation of K562/ADR cells and drug resistance. 5 In this 5 
study, the results confirmed that CD147 was a specific substrate of ST8SIA4 6 
sialyltransferase, rather than a relevant substrate of ST3GAL5 sialyltransferase 7 
(Supplementary Figure S1). 8 
PI3K/Akt signaling pathway is reported to be over-activated in AML cells and 9 
plays an essential role in proliferation, drug resistance, motility, invasion and 10 
inhibition of apoptosis in cancer cells. 32-35 PI3K/Akt inhibition modulates MDR and 11 
activates NF-κB in murine lymphoma cell lines.36 Inhibition of the PI3K/mTOR 12 
pathway is a promising therapeutic approach in patients with acute lymphoblastic 13 
leukemia.37 A number of studies have also demonstrated that GM3 gangliosides 14 
inhibit phosphorylation of the epidermal growth factor receptor (EGFR) that results in 15 
inhibition of PI3K/Akt signaling in varied cell types.38, 39 NCAM-mediated adhesion 16 
leads to activation of various intracellular signal transduction pathways, including the 17 
Ras-mitogen activated protein kinase (MAPK) and the PI3K/Akt pathways.40 In this 18 
study we found that a novel mechanism by which MDR of AML cells can be 19 
developed and changed, i.e. MDR is induced though activation of the PI3K/Akt 20 
pathway by sialylation modification. The resistant cell line HL60/ADR exhibited 21 
higher PI3K/Akt activity than the sensitive one, which was in accordance with the 22 
 17
MDR phenotype. Suppression of ST3GAL5 or ST8SIA4 markedly modulated the 1 
activity of PI3K/Akt pathway and its downstream target NF-κB and mTOR in AML 2 
cell lines (Figure 7a-d and Supplementary Figure S2). In addition, inhibition of the 3 
PI3K/Akt pathway with LY294002 or Akt gene silencing by siRNA pretreatment 4 
reversed chemoresistance of HL60/ADR cells (Figure 8b.c). These results indicated 5 
that ST3GAL5 or ST8SIA4-modulated MDR in AML cell lines is, at least in part, 6 
PI3K/Akt-dependent.  7 
To date, tremendous evidence indicates that tumor cells maintain the MDR 8 
through the PI3K/Akt pathway enhancing drug efflux by ATP-binding cassette (ABC) 9 
transporters.41 As two main members of ABC transporters, P-gp and MRP1 are 10 
frequently used as markers to screen MDR patients clinically. PI3K inhibitor, 11 
LY294002, therefore has therapeutic potential in the treatment of MRP1-mediated 12 
drug resistance when combined with doxorubicin, 42 since it is able to block P-gp 13 
expression in mouse leukemic cell lines.43 A recent report in acute myelogenous 14 
leukemia has demonstrated that MRP-1 but not P-gp efflux was inhibited by the PI3K 15 
inhibitor wortmannin.41 Moreover, constitutive activation of PI3K/Akt is associated 16 
with the expression of ST3GAL5 and ST8SIA4.38-40 Therefore, a close association is 17 
found between the levels of ST3GAL5 and ST8SIA4 and the levels of phosphorylated 18 
Akt, as well as P-gp, MRP1 expression in leukemic cells. In this study, we showed 19 
that, the levels of P-gp and MRP1 had a proportional relationship with the expression 20 
of ST3GAL5 or ST8SIA4 and the activity of PI3K/Akt signaling in HL60 or 21 
HL60/ADR cell lines. Since ST3GAL5 or ST8SIA4 was observed as regulatory gene 22 
 18
for the activity of PI3K/Akt signaling, we assume that ST3GAL5 or ST8SIA4 might 1 
regulate the expression of P-gp and MRP1 through PI3K/Akt pathway, thereby 2 
promoting MDR of leukemia cells.  3 
Although the clinical outcome of AML has been improved with advancements in 4 
chemotherapy, MDR remains a critical challenge for successful treatment. A great 5 
number of AML (including M2, M3 and M5) patients were examined and analyzed in 6 
the present study, while more than 90% of the AML patients were found resistant to 7 
the anticancer drugs. ST3GAL4, ST6GAL1, ST6GALNAC4 and ST8SIA4 were 8 
expressed at a high level in BMMC of a significant proportion of M2/MDR, 9 
M3/MDR and M5/MDR patients, whereas expression of ST3GAL1, ST3GAL5 and 10 
ST8SIA6 were at a high level in BMMC of a number of cases M2, M3 and M5 11 
without MDR. Once again the findings from the clinical samples confirm that altered 12 
levels of these genes were probably associated with MDR phenotype in AML. On the 13 
basis of the above results, it might be possible to utilize differential expressional ST 14 
genes as useful leukemia biomarkers for clinical diagnosis of drug resistant leukemia 15 
and as potential targets for therapeutic approaches in the future.  16 
In summary, our work reveals differential expression patterns of ST genes in 17 
three pairs of AML cell lines and in BMMC of the AML patients. Altered ST3GAL5 18 
and ST8SIA4 presented the unusual property of association with MDR of AML cells 19 
via regulating the PI3K/Akt signaling pathway and the expression of P-gp and MRP1. 20 
MDR in AML is a multifactorial phenomenon and targeting these molecules seems to 21 
be a feasible approach to clinical diagnosis and treatment of MDR AML. 22 
 19
MATERIALS AND METHODS 1 
Parental AML cell culture  2 
Three AML cell lines, including an acute myelogenous leukemia (M2) cell line HL60, 3 
an acute promyelocytic leukaemia (M3) cell line NB4, and a leukemic monocytic 4 
lymphoma (M5) cell line U937 were obtained from the KeyGEN Company (China). 5 
All cell lines were cultured as previously described.52 Adriamycin (Sigma) was added 6 
to parental cell cultures in stepwise increasing concentrations from 0.1μg/ml to 7 
5μg/ml for 2 months to develop an adriamycin-resistant (ADR) subline, namely 8 
HL60/ADR, NB4/ADR and U937/ADR, correspondingly. To maintain the MDR 9 
phenotype, the complete medium of the resistant cell clones were supplemented with 10 
1.0 mg/L adriamycin. ADR cells were maintained in complete medium without 11 
adriamycin for one week and cells with >90% viability prior to subsequent treatments. 12 
 13 
Samples from leukemia patients 14 
76 previously untreated AML patients comprising 53 males and 23 females, with age 15 
ranging from 12 to 79 years (median age of 42 years) and 7 healthy donors were 16 
included in this study. The diagnosis of AML was based on cytomorphology, 17 
cytochemistry, multiparameter flow cytometry, immunology, molecular genetics and 18 
cytogenetics, and the leukemic subtypes of AML were determined according to the 19 
French-American-British classification as follows: 35, 27 and 14 cases of M2, M3 and 20 
M5, respectively. All AML patients who were obtained from June 2010 to May 2012 21 
at the First Affiliated Hospital of Dalian Medical University (Dalian, China) provided 22 
 20
written informed consent, and the institutional ethics committees approved the study 1 
as well as contents of the written consent. Bone marrow samples were collected at 2 
diagnosis and before treatment. BMMC were isolated by Ficoll-Hypaque density 3 
gradient centrifugation and were cultured in plastic dishes to remove adherent cells at 4 
37°C for 24 h. Freshly separated non-adherent cells were maintained in modified 5 
Dulbecco’s medium containing 10% fetal bovine serum, 10 mM β-mercaptoethanol, 2 6 
mM L-glutamine, 50 ng/mL human stem cell factor, 10 ng/mL human interleukin-3, 7 
and 10 ng/mL human interleukin-6. Patients’ clinical characteristics were given in 8 
Table 2.  9 
 10 
Membrane protein extract and release of N-glycans from cell membrane proteins 11 
Membrane protein extract has been described previously.8 For releasing of N-glycans, 12 
three 100 μg aliquots of lyophilized cell membrane proteins were first digested with 13 
trypsin (10 μg) and chymotrypsin (10 μg) dissolved in 25 mM ammonium bicarbonate 14 
(25 μL) at 37°C for 18 h. The digest was left in a water bath (85°C, 5 min) and after 15 
cooling N-linked oligosaccharides were released from peptides by treatment with 16 
PNGaseF enzyme (2μL; 6U) at 37°C (18 h) followed by Pronase digestion (10 μg) at 17 
37°C (8 h). During the incubation time, the reaction sample was mixed occasionally. 18 
The released N-glycans were purified using an Oasis HLB cartridge (60 mg/3ml; 19 
Waters) and then were lyophilized. 20 
 21 
MS analysis 22 
 21
The mass spectra were carried out in reflectron positive ion mode with MALDI-TOF 1 
MS ((Bruker Corp., Billerica, MA, USA). To increase sensitivity and provide more 2 
informative fragmentation, the released glycans were permethylated and further 3 
characterized by MALDI-TOF MS. For the type of MALDI analysis of the 4 
permethylated glycans, 2, 5-DHB was used as the matrix. All MS spectra were 5 
obtained from Na+ adductions. 6 
 7 
Real Time PCR analysis  8 
Total RNA was isolated with Trizol reagents (Gibco BRL, Rockville, MD, USA),   9 
treated by QuantiTect Reverse Transcription Kit (QIAGEN, valencia, CA) and 10 
QuantiTect SYBR Green PCR Kit (QIAGEN, valencia, CA). The primer pairs for 11 
PCR are listed in Table 1. Level of GAPDH mRNA was measured for standardization 12 





Western blot analysis 15 
Western blot analysis was carried out as described previously.52 Briefly, samples (20 16 
μg protein) were subjected to SDS–PAGE. After transfer of proteins onto the 17 
polyvinylidene difluoride membrane, the blots were probed with the following 18 
antibodies: rabbit anti-human ST8Sia IV, ST3Gal V, PI3K p110α, p-Akt 308, p-Akt 19 
473, Akt, NF-κB antibodies (Abgent, Cambridge, UK, 1:1000 dilution), and then 20 
incubated with secondary antibody anti-rabbit-HRP (1:2000 diluted, Santa Cruz 21 
Biotech, Santa Cruz, CA). CD147, mTOR, p-mTORser2448, p-p70S6KThr389, and 22 
 22
GAPDH antibody (1:200 diluted, Santa Cruz Biotech, Santa Cruz, CA) was used as a 1 
control. 2 
 3 
Deregulation of ST3GAL5 or ST8SIA4 by RNAi 4 
RNAi was performed as previously described.52 The cell cultures were transfected 5 
with ST3GAL5 or ST8SIA4 specific shRNA, and scrambled shRNA used as the 6 
negative control. ST3GAL5 shRNA or ST8SIA4 shRNA was mixed with 7 
LipofectamineTM 2000 (Invitrogen). Transfer cells were cultured and incubated at 8 
37◦C for 6 h, followed by incubation with complete medium for additional 24h. The 9 
cell transfection efficiency was 85% by fluorescent microscope and the cell viability 10 
was 90 % by trypan blue dye exclusion assay. 11 
 12 
Over-expression of ST3GAL5 or ST8SIA4 13 
The human ST3GAL5 and ST8SIA4 coding sequences were obtained from TaKaRa 14 
company (Dalian, China) and were inserted into the pEGFP-N2 vector (Invitrogen, 15 
Carlsbad, CA) respectively using EcoRI, XhoI sites. Cells were transfected with 5μg 16 
of target gene expression vector or empty vector (EV) in 100-mm dishes using 17 
PolyFect Transfection Reagent (QIAGEN, valencia, CA) according to the 18 
manufacturer’s instruction. After 4 weeks of screening, the cell lines stably expressing 19 
ST3GAL5 (HL60/ADR/ST3GAL5) and ST8SIA4 (HL60/ST8SIA4), empty vector 20 
(HL60/ADR/mock, HL60/mock) were established. The cell transfection efficiency 21 
was 79% and the survival rate was 90%. 22 
 23
 1 
In vitro drug cytotoxic assay 2 
Drug resistance was evaluated by MTT assay as previously described.52 Briefly, Cells 3 
(1×104) were plated in 96-well plate and allowed to grow for 48 h before the addition 4 
of MTT. The spectrometric absorbance was measured at 490 nm by microplate reader 5 
(Model 680; Bio-Rad, Hercules, CA).  6 
 7 
In vivo chemosensitivity assay 8 
Animal studies were performed as previously described.52 Briefly, when mice bearing 9 
palpable tumors, HL60, HL60/mock, HL60/ST8SIA4, HL60-control shRNA, 10 
HL60-ST3GAL5 shRNA-1, HL60/ADR, HL60/ADR/ST3GAL5, HL60/ADR-control 11 
shRNA, HL60/ADR-ST8SIA4 shRNA-1 tumor-bearing mice were randomly divided 12 
into control and treatment groups (n=6 animals per group). The treatment groups 13 
received 7 mg/kg adriamycin i.p. three times a week for 3 weeks, and the control 14 
groups received physiological saline alone. The tumor volume was calculated by the 15 
following formula: Tumor volume = 1/2(length × width2).  16 
 17 
Immunohistochemical (IHC) staining analysis 18 
Visible tumors were removed from the mice and immunohistochemistry was 19 
performed on paraffin embedded sections. The slides were dried, deparaffinized, 20 
rehydrated. After deparaffinization and blocking of endogenous peroxidase, the slides 21 
were labeled overnight at 4°C with antibodies (Abcam, Cambridge, UK) at a dilution 22 
 24
of 1:200. The following staining was performed at 37°C for 60min with secondary 1 
streptavidin-HRP-conjugated antibody (Santa Cruz Biotech, Santa Cruz, CA). Finally, 2 
the sections were counterstained with hematoxylin and cover-slipped.  3 
 4 
Inhibition of the PI3K/Akt signaling 5 
LY294002 (Sigma) or Akt siRNA was used to suppress the activity of the PI3K/Akt 6 
signaling in HL60/ADR cells. Briefly, cells (1×104 cells per well) were incubated with 7 
DMSO, the PI3K inhibitor LY294002 (10 μM) dissolved in DMSO, Akt control 8 
siRNA and Akt siRNA, and collected after 24 h.  9 
 10 
Flow cytometry analysis 11 
Flow cytometry analysis has been described previously.52 For surface staining of P-gp 12 
and MRP1, aliquots of cells were incubated with fluorescein isothiocyanate 13 
(FITC)-anti human P-gp, MRP1 (Abcam, Cambridge, UK) or an isotype control 14 
antibody (Santa Cruz Biotech, Santa Cruz, CA). For detection of α-2, 3 andα-2, 8 15 
sialylation, cell lysates were incubated with FITC-MAL or Sig 7 lectin (Sigma, St 16 
Louis, MO, USA). After repeated centrifugation at 1000 r/min, labeled cells were 17 
resuspended in 0.2 ml PBS and were analyzed with FACSCalibur (BD Biosciences, 18 
San Jose, CA, USA).  19 
 20 
Statistical analysis 21 
Data were expressed as mean± SD and Student’s t-test was carried out. P < 0.05 was 22 
 25
considered statistically significant. 1 
 2 
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Figure legends 22 
 31
Figure 1. Differential N-glycan composition of HL60 and HL60/ADR cell lines. (a) MALDI-TOF 1 
MS spectra of permethylated N-glycans released from HL60 and HL60/ADR cells, respectively. 2 
(b) Histograms of relative intensities of the differential glycan signals were observed. The signals 3 
indicated with Arabic numerals are summarized in Table 4. 4 
 5 
Figure 2. Differential expression of ST gene family in three pairs of AML cell lines. (a-e) The 6 
mRNA levels of ST gene family analyzed by real-time PCR. The relative amount of gene 7 
mRNA level was normalized to GAPDH level. Three MDR cells expressed higher levels of 8 
ST3GAL4, ST6GAL1, ST6GALNAC4 and ST8SIA4 mRNA, while their parental cell types 9 
expressed higher levels of ST3GAL1, ST3GAL5 and ST8SIA6 mRNA (*P<0.05). Data are the 10 
means ± SD of triplicate determinants. 11 
 12 
Figure 3. Silence of ST8SIA4 gene facilitates HL60/ADR cells sensitive both in vitro and in vivo. 13 
(a) Silencing of ST8SIA4 in HL60/ADR cells was analyzed by RNAi approach. ST8SIA4 14 
transcripts were decreased apparently in HL60/ADR cells by shRNA treatment. (b) After shRNA 15 
transfection, distinct reduction of ST8SIA4 was observed at protein levels by western blot analysis. 16 
(c) Flow cytometry analysis showed α-2, 8 sialylation level detected by FITC-conjugated Siglec7 17 
on the cell surface, was also reduced in HL60/ADR-ST8SIA4 shRNA1 cells. (d) Cell 18 
chemosensitivity was assessed by cytotoxicity assays. The reported values were the IC50 (Mean ± 19 
SD) of three independent experiments. IC50 represents the drug concentration producing 50% 20 
decrease of cell growth. *P<0.05 vs HL60/ADR cells. **P<0.05 vs HL60/ADR-control shRNA 21 
cells. (e) A decrease of mean tumor volume in mice group with HL60/ADR-ST8SIA4 shRNA1 22 
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tumors was observed, as compared to the control group. Within HL60/ADR-ST8SIA4 shRNA1 1 
group, a decrease of tumor growth was found in group with ADR, compared with that without 2 
ADR (*P<0.05). (f) Reduced regulation of ST8Sia IV was also shown by IHC staining in 3 
xenograft tumors derived from HL60/ADR-ST8SIA4 shRNA1 cells (400×). The data are means ± 4 
SD of 3 independent assays (*P<0.05).  5 
 6 
Figure 4. Overexpression of ST8SIA4 mediates the acquirement of MDR in HL60 cells. After 7 
full-length sequences transfection, ST8SIA4 mRNA (a) and protein (b) were increased notably in 8 
HL60 cells by real time PCR and western blot. (c) Flow cytometry analysis showed α-2, 8 9 
sialylation level detected by FITC-conjugated Siglec-7 on the cell surface, was also increased in 10 
HL60/ ST8SIA4 cells. The chemoresistance of HL60 cells was increased with the 11 
ST8SIA4 expression vector transfection in vitro (d) and in vivo (e). (f) Up-regulation of 12 
ST8Sia IV was also shown by IHC staining in xenograft tumors derived from HL60/ST8SIA4 13 
cells (400×). The data are means ± SD of 3 independent assays (*P<0.05).  14 
 15 
Figure 5. Silence of ST3GAL5 gene increases the chemoresistance of HL60 cells both in vitro 16 
and in vivo. After transfection, ST3GAL5 mRNA (a) and protein (b) were reduced notably in 17 
HL60 cells. (c) Fluorescence intensity on MAL revealed less α-2, 3 sialylation in HL60-ST3GAL5 18 
shRNA1 cells than that in nontransfection cells. The chemoresistance of HL60 cells was increased 19 
with the ST3GAL5 shRNA1 transfection in vitro (d) and in vivo (e). (f) Down-regulation of 20 
ST3Gal V was also shown by IHC staining in xenograft tumors derived from HL60-ST3GAL5 21 
shRNA1 cells (400×). The data are means ± SD of 3 independent assays (*P<0.05).  22 
 33
 1 
Figure 6. Overexpression of ST3GAL5 gene enhances the chemosensitivity of HL60/ADR cells 2 
both in vitro and in vivo. (a-b) Higher levels of ST3GAL5 were detected in HL60/ADR/ST3GAL5 3 
cells. (c) Fluorescence intensity on MAL revealed higher α-2, 3 sialylation in 4 
HL60/ADR/ST3GAL5 cells than that in nontransfection cells. The chemosensitivity of 5 
HL60/ADR cells was increased with the ST3GAL5 expression vector transfection in vitro (d) and 6 
in vivo (e). (f) IHC staining showed an enhanced expression of ST3Gal V in xenograft tumors 7 
derived from HL60/ADR/ST3GAL5 cells (400×). The data are means ± SD of 3 independent 8 
assays (*P<0.05). 9 
 10 
Figure 7. Effect of ST8SIA4 or ST3GAL5-activated PI3K/Akt/NF-κB signaling pathway on the 11 
expression of P-gp and MRP1. (a-d) Expression of PI3K/Akt/NF-κB signaling molecules were 12 
altered at protein levels with ST8SIA4 shRNA1 and ST8SIA4 expression vector transfection in 13 
HL60 cells or ST3GAL5 shRNA1 and ST3GAL5 expression vector transfection in HL60/ADR 14 
cells. Flow cytometry analysis revealed a higher expression of P-gp and MRP1 in 15 
HL60-ST3GAL5 shRNA-1 (g) or HL60/ST8SIA4 cells (f). Decreased expression of P-gp and 16 
MRP1 were examined by flow cytometry analysis in HL60/ADR-ST8SIA4 shRNA-1 (e) or 17 
HL60/ADR/ST3GAL5 cells (H). The data are means ± SD of 3 independent assays (*P<0.05). 18 
 19 
Figure 8. PI3K/Akt inhibition modulates the chemosensitivity of HL60/ADR cells both in vitro 20 
and in vivo. (a) The HL60/ADR cells were pretreated LY294002 or Akt siRNA. Expression of 21 
PI3K/Akt/NF-κB signaling molecules were then examined by western blot analysis. LY294002 or 22 
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Akt siRNA treatment also alleviated chemoresistance of HL60/ADR cells, revealed by in vitro (b) 1 
and in vivo (c). (d) Down-regulation of PI3K/Akt signaling molecules was also shown by IHC 2 
staining in xenograft tumors derived from LY294002 or Akt siRNA treatment cells (400×). (e) 3 
Flow cytometry analysis showed that suppression of PI3K/Akt signaling resulted in reduced level 4 
of P-gp and MRP1. The data are means ± SD of 3 independent assays. *P<0.05 vs DMSO 5 












Table1 qRT-PCR conditions and primer sequences for analysis of gene expression 
Gene Primers Amplicon 
ST3GAL1 5'-CAGAGATGGACGGTCACT-3'; 5'-CAACTGTGGTTTCTGACG-3' 197bp 
ST3GAL2 5'-GTGCCTCCGACTGGTTTG-3'; 5'-GAAGCGGTAGGGGTTCTC-3' 191bp 
ST3GAL3 5'-TATGCTTCAGCCTTGATG-3'; 5'-TTGGTGACTGACAAGATGG-3' 164bp 
ST3GAL4 5'-ATGTTGGCTCTGGTCCTG-3'; 5'-AGGAAGATGGGCTGATCC-3' 176bp 
ST3GAL5 5'-CAAAGCAAGATGAGAAGG-3'; 5'-AAACTTGGGACGACATTC-3' 213bp 
ST3GAL6 5'-ATGTCTATTGGGTGGCAC-3'; 5'-CGCACACAGAAAAGGGTG-3' 189bp 
ST6GAL1 5'-CTTGTTTTCCTGCTCAGA-3'; 5'-GCAAACAGAAGAAAGACCA-3' 166bp 
ST6GAL2 5′-ACGCTGCTGATTGACTCTTCT-3′; 5′-CACATACTGGCACTCATCTAA-3′ 160bp 
ST6GALNAC1 5'-CTGGTCTTCTTTCTCTTCG-3'; 5'-GTTGAGGGCATTGTTCTCT-3' 192bp 
ST6GALNAC2 5'-CTTTGCCCTGTACTTCTCG-3'; 5'-CAGCACTGGAATGGAGAGA-3' 205bp 
ST6GALNAC3 5'-GGACAACCTGGTACAAAGT-3'; 5'-TATCTCATTTCCCACCTTC-3' 174bp 
ST6GALNAC4 5'-ACCTGCCTGGACCACCACT-3'; 5'-TCGGCACTGTCGATCTCAG-3' 188bp 
ST6GALNAC5 5'-TGGACGGATACCTCGGAGT-3'; 5'-GTCTGGTCAATCTGGGAGC-3' 121bp 
ST6GALNAC6 5'-ACCTACCCCTCAGCAGACG-3'; 5'-CTTGAGGTTGACAGGTCGG-3' 179bp 
ST8SIA1 5'-TACTCTCTCTTCCCACAGG-3'; 5'-GACAAAGGAGGGAGATTGC-3' 149bp 
ST8SIA2 5'-GTGGTCTTCCTCATCTTCG-3'; 5'-GAGGAGCCGTTTATTACAAC-3' 140bp 
ST8SIA3 5'-ATTCTCTCACCCAGGAACTC-3'; 5'-CAATCCGAACACTATTCTTG-3' 141bp 
ST8SIA4 5'-CAAGAACTGAGGAGCACC-3'; 5'-TTTCCAACCTTCTACATTGTG-3' 140bp 
ST8SIA5 5'-CCTTTGCCTTGGTGACCT-3'; 5'-CATGGACAGCACCTTCACT-3' 152bp 
ST8SIA6 5'-CGGCAAGCAGAAGAATATG-3'; 5'-GCTTTCCACCTCGTAACTC-3' 126bp 




Table 2 Clinicopathologic characteristics of the leukemia patients 
 
Patients Demographics Subcategory  AML(n=76)  
M2 M3 M5
Gender Male 24 19 10 
- Female 11 8 4 
Age(years) Median 42 44 38 
- Range 15-79 18-70 12-70 
Splenic enlargement - 25 18 10 
Hemoglobin<110.0g/l - 34 25 12 
WBC count (109/L) 20-100 19 17 7 
 >100 2 0 1 
Platelet count (109/L) <300 32 26 14 
 >300 3 1 0 
P-gp (+) - 33 24 12 
MRP1 (+) - 31 23 12 
Table 3 N-Glycans analyzed in HL60 and HL60/ADR cell lines by MALDI-TOF MS 
Peak no. 
Observed  m/z Composition 
HL60/ADR HL60 Hex HexNAc Man GlcNAc NeuAc Deoxyhexose 
1 1345.65 1345.80 0 0 3 2 0 1 
2 1375.63 1375.88 1 0 3 2 0 0 
3 1416.77 1416.85 0 1 3 2 0 0 
4 1579.73 1579.88 0 0 5 2 0 0 
5 1662.11 No 0 2 3 2 0 0 
6 1784.09 1784.08 0 0 6 2 0 0 
7 1795.07 1795.23 1 1 3 2 0 1 
8 1835.77 1836.07 0 2 3 2 0 1 
9 1987.92 1988.07 0 0 7 2 0 0 
10 2029.19 2029.31 3 1 3 2 0 0 
11 2081.23 2081.39 0 3 3 2 0 1 
12 2186.30 2186.17 2 1 3 2 1 0 
13 2191.95 2192.14 0 0 8 2 0 0 
14 2244.39 2244.28 2 2 3 2 0 1 
15 2360.07 2360.17 2 1 3 2 1 1 
16 2396.00 2396.20 0 0 9 2 0 0 
17 2431.00 2431.20 2 2 3 2 1 0 
18 2564.05 2564.27 3 1 3 2 1 1 
19 2605.04 2605.25 2 2 3 2 1 1 
20 2693.03 2693.25 3 3 3 2 0 1 
21 2779.10 2779.32 2 2 3 2 1 2 
22 2792.09 2792.33 2 2 3 2 2 0 
23 2850.68 2850.83 2 3 3 2 1 1 
24 2880.07 2880.23 3 3 3 2 1 0 
25 2967.68 2967.91 2 2 3 2 2 1 
26 3054.15 3054.38 3 3 3 2 1 1 
27 3142.26 3142.43 4 4 3 2 0 1 
28 3418.41 3418.52 3 3 3 2 2 1 
29 3503.03 3503.43 4 4 3 2 1 1 
30 3602.85 No 3 3 3 2 3 0 
31 3776.20 3777.36 3 3 3 2 3 1 
32 3864.92 3864.49 4 4 3 2 2 1 
33 3952.49 3952.28 5 5 3 2 1 1 
34 4225.52 4226.71 4 4 3 2 3 1 
35 4314.81 4314.38 5 5 3 2 2 1 
The N-glycans were observed as [M+Na]+. 
Hex, hexose; HexNAc, N-acetylhexosamine; Man, mannose; GlcNAc, N-acetylglucosamine;  
NeuAc, N-acetylneuraminic acid. 
Table 4 Expressional profiles of ST gene family in AML/MDR and AML patients 
Gene 
Relative mRNA expression (×10³) 
P-value 
Relative mRNA expression (×10³) 
P-value 
Relative mRNA expression (×10³) 
P-value 













































































































































*P<0.05 vs M2 patients, **P<0.05 vs M3 patients, ***P<0.05 vs M5 patients. 
 
